BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 25155261)

  • 1. KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.
    Li W; Shi Q; Wang W; Liu J; Ren J; Li Q; Hou F
    Colorectal Dis; 2014 Nov; 16(11):O370-8. PubMed ID: 25155261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
    Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.
    Chen J; Ye Y; Sun H; Shi G
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):265-72. PubMed ID: 23090619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB; Wang Q; Hu WG
    World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
    Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies.
    Qiu LX; Mao C; Zhang J; Zhu XD; Liao RY; Xue K; Li J; Chen Q
    Eur J Cancer; 2010 Oct; 46(15):2781-7. PubMed ID: 20580219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
    Lv ZC; Ning JY; Chen HB
    Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
    Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
    Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
    Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
    Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
    Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
    Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
    Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
    Gajate P; Sastre J; Bando I; Alonso T; Cillero L; Sanz J; Caldés T; Díaz-Rubio E
    Clin Colorectal Cancer; 2012 Dec; 11(4):291-6. PubMed ID: 22537608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
    J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.
    Mao C; Qiu LX; Liao RY; Du FB; Ding H; Yang WC; Li J; Chen Q
    Lung Cancer; 2010 Sep; 69(3):272-8. PubMed ID: 20022659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.